Covered recipient · General Payments record
TIRRELL T JOHNSON
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$303.63
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $303.63 | 4 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $157.03 | 2 |
| AstraZeneca Pharmaceuticals LP | $146.60 | 2 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TIRRELL T JOHNSON
NPI 1518042415 · CMS profile ID 204048
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ORLANDO, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518042415?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518042415?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518042415?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1518042415?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $303.63 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $113.96 | 12/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206984068 | CMS |
| Janssen Biotech, Inc. | $137.65 | 05/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175188887 | CMS |
| Janssen Biotech, Inc. | $19.38 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175189961 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.64 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206458621 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,665,235.05 | 404 |
| PY2024 | Principal investigator | $475,494.74 | 62 |
| PY2023 | Principal investigator | $95,270.20 | 17 |
| PY2022 | Principal investigator | $226,118.71 | 15 |
| PY2021 | Principal investigator | $31,342.00 | 7 |
| PY2020 | Principal investigator | $82,456.06 | 7 |
| PY2019 | Principal investigator | $37,669.74 | 6 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
62 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $58,389.20 | 12/31/2024 | Covered Recipient Teaching Hospital Orlando Health | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOTE 158 | No dispute reported | 06/30/2026 | 1136409990 |
| Principal investigator 2 | Merck Sharp & Dohme LLC | $129,632.72 | 12/31/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 | No dispute reported | 06/30/2026 | 1136437777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $83.84 | 12/26/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405176 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $53.71 | 12/26/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405178 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 12/26/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405180 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 12/26/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405182 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $561.99 | 12/26/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405184 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,426.12 | 12/26/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $73.36 | 12/26/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,140.00 | 12/23/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1079009012 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,080.00 | 12/23/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1079009032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,082.70 | 12/18/2024 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086073102 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,163.00 | 12/16/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1079008982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $770.00 | 12/16/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1079008984 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 12/16/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | No dispute reported | 06/30/2026 | 1079008990 |
| Principal investigator 1 | ModernaTX, Inc. | $1,403.01 | 12/13/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma | No dispute reported | 06/30/2026 | 1147149818 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $794.00 | 12/05/2024 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086073094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $725.09 | 12/04/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405096 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,082.70 | 11/18/2024 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086073090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 11/14/2024 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086073088 |
| Principal investigator 1 | ModernaTX, Inc. | $4,873.20 | 11/06/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma | No dispute reported | 06/30/2026 | 1147149816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,299.05 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405042 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405044 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,716.94 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405046 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,557.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $334.05 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405050 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $334.05 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,299.05 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405056 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405058 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405060 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405062 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405064 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,716.94 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405066 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405068 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405070 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,557.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405072 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,784.12 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405074 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $334.05 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.90 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405078 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $334.05 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405080 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,299.05 | 10/25/2024 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer | No dispute reported | 06/30/2026 | 1082405082 |
| Principal investigator 1 | ModernaTX, Inc. | $2,252.48 | 10/21/2024 | Covered Recipient Teaching Hospital Orlando Health | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1147149950 |
| Principal investigator 1 | ModernaTX, Inc. | $7,151.81 | 10/16/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma | No dispute reported | 06/30/2026 | 1147149812 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 10/03/2024 | Covered Recipient Teaching Hospital Orlando Health | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1147149948 |
| Principal investigator 1 | ModernaTX, Inc. | $9,746.40 | 10/02/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma | No dispute reported | 06/30/2026 | 1147149814 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 09/18/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma | No dispute reported | 06/30/2026 | 1147149774 |
| Principal investigator 1 | Janssen Research & Development, LLC | $294.00 | 08/22/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1079009002 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $39,272.00 | 08/12/2024 | Covered Recipient Teaching Hospital Orlando Health | Ph II/III IO Naive Mel (lag3 + nivo FDC) - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma | No dispute reported | 06/30/2026 | 1123473993 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 08/08/2024 | Non-covered Recipient Entity Regional Cancer Care Associates Admin Office | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086069362 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $569.07 | 06/26/2024 | Non-covered Recipient Entity Orlando Health Cancer Institute-Downtown Orlando | PhI in 1L SCLC with BI 764532 + chemo plus anti PD-L1 | No dispute reported | 06/30/2026 | 1155144986 |
| Principal investigator 1 | Janssen Research & Development, LLC | $170.00 | 05/24/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1079009008 |
| Principal investigator 1 | PFIZER INC. | $7,540.00 | 05/09/2024 | Covered Recipient Teaching Hospital Orlando Health | A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY EXTENSIVESTAGE SMALL CELL LUNG CANCER TRIOUS L07 | No dispute reported | 06/30/2026 | 1131035310 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 04/18/2024 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086073070 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $89,309.10 | 03/25/2024 | Covered Recipient Teaching Hospital Orlando Health | PhI in 1L SCLC with BI 764532 + chemo plus anti PD-L1 | No dispute reported | 06/30/2026 | 1101069391 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 01/29/2024 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086073060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,618.00 | 01/26/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1079008980 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,090.46 | 01/25/2024 | Non-covered Recipient Entity Orlando Health Medical Group Inc | PhI in 1L SCLC with BI 764532 + chemo plus anti PD-L1 | No dispute reported | 06/30/2026 | 1101069111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,787.00 | 01/22/2024 | Covered Recipient Teaching Hospital Orlando Health | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1079008974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $930.17 | 01/18/2024 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1086073048 |